Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.

Di Leo A, Malorni L.

J Clin Oncol. 2012 Jun 1;30(16):1897-900. doi: 10.1200/JCO.2012.41.7394. Epub 2012 Apr 30. No abstract available.

PMID:
22547606
2.

Anastrozole and fulvestrant in metastatic breast cancer.

Tempfer C.

N Engl J Med. 2012 Oct 25;367(17):1663; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA3. No abstract available.

PMID:
23094734
3.

Anastrozole and fulvestrant in metastatic breast cancer.

Ramaekers R, Jabbour M, Copur MS.

N Engl J Med. 2012 Oct 25;367(17):1662-3; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA2. No abstract available.

PMID:
23094733
4.

Anastrozole and fulvestrant in metastatic breast cancer.

Lintermans A, Vanderhaegen J, Neven P.

N Engl J Med. 2012 Oct 25;367(17):1662; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA1. No abstract available.

PMID:
23094732
5.

Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.

Goldhirsch A, Gelber RD.

Nat Rev Clin Oncol. 2012 Oct;9(10):556-7. doi: 10.1038/nrclinonc.2012.155. Epub 2012 Sep 4. No abstract available.

PMID:
22949048
6.

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R.

J Clin Oncol. 2012 Jun 1;30(16):1919-25. doi: 10.1200/JCO.2011.38.1095. Epub 2012 Feb 27.

PMID:
22370325
7.

Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.

Yardley DA, Burris HA 3rd, Clark BL, Shipley D, Rubin M, Barton J Jr, Arrowsmith E, Hainsworth JD.

Clin Breast Cancer. 2011 Jun;11(3):146-52. doi: 10.1016/j.clbc.2011.03.010. Epub 2011 Apr 20.

PMID:
21665134
8.

A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma.

Zagouri F, Dimitrakakis C, Dimopoulos MA, Tsigginou A, Antsaklis A, Papadimitriou CA.

Breast J. 2012 Nov-Dec;18(6):628-9. doi: 10.1111/tbj.12019. Epub 2012 Sep 26. No abstract available.

PMID:
23009609
9.

Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.

Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A.

Cancer Res. 2008 May 1;68(9):3516-22. doi: 10.1158/0008-5472.CAN-07-6807.

10.

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

Vergote I; Faslodex 0020 and 0021 Investigators.

Eur J Cancer. 2002 Nov;38 Suppl 6:S57-8. No abstract available.

PMID:
12409076
11.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

12.

Combination endocrine treatments unproven in breast cancer.

Buzdar AU.

Lancet Oncol. 2013 Sep;14(10):917-8. doi: 10.1016/S1470-2045(13)70364-4. Epub 2013 Jul 29. No abstract available.

13.

[Therapy concept: herceptin in combination with arimidex].

von Minckwitz G.

Onkologie. 2002 Dec;25 Suppl 5:22 ; discussion 22-4. German. No abstract available.

PMID:
23573617
14.

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V.

J Clin Oncol. 2010 Sep 1;28(25):3917-21. doi: 10.1200/JCO.2009.24.9565. Epub 2010 Aug 2.

PMID:
20679610
15.

Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?

Overmoyer B.

J Clin Oncol. 2015 Mar 10;33(8):823-8. doi: 10.1200/JCO.2014.58.2361. Epub 2015 Jan 26. No abstract available.

PMID:
25624431
16.

Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.

Krell J, Ewart EK, Stebbing J.

Eur J Cancer. 2010 Nov;46(16):2867-9. doi: 10.1016/j.ejca.2010.08.021. Epub 2010 Sep 27. No abstract available.

PMID:
20880696
17.

Update on ATAC.

[No authors listed]

Eur J Cancer. 2003 Feb;39(3):269. No abstract available.

PMID:
12632577
18.

Palbociclib ups PFS in HER2-/ER+ breast cancer.

[No authors listed]

Cancer Discov. 2014 Jun;4(6):624-5. doi: 10.1158/2159-8290.CD-NB2014-053. Epub 2014 Apr 6. No abstract available.

19.

Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.

Watanabe N, Ootawa Y, Kodama K, Kaide A, Ootsuka N, Matsuoka J.

Breast Cancer. 2010 Oct;17(4):247-53. doi: 10.1007/s12282-009-0144-6. Epub 2009 Sep 1.

PMID:
19728030
20.

Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M.

J Clin Oncol. 2011 Jul 1;29(19):2653-9. doi: 10.1200/JCO.2010.33.2585. Epub 2011 May 9.

PMID:
21555684

Supplemental Content

Support Center